[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615220":3},{"organization":4,"outcomesModule":7,"designInfo":119,"detailedDescription":130,"studyPopulation":118,"armGroups":131,"interventions":145,"overallOfficials":118,"centralContacts":163,"locations":172,"responsibleParty":192,"collaborators":118,"id":194,"slug":195,"hasResults":196,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":118,"eligibilityCriteria":200,"healthyVolunteers":201,"sex":202,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":118,"studyType":208,"phases":209,"briefSummary":211,"conditions":212,"keywords":118,"overallStatus":175,"whyStopped":118,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},{"fullName":5,"class":6},"Grünenthal GmbH","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":118},[9,13],{"measure":10,"description":11,"timeFrame":12},"Number of participants with Adverse Events","An AE is defined as any unfavorable medical occurrence in a trial participant administered the investigational product.\n\nAssessment of the safety and tolerability of GRT7041 after oral single and multiple-dose escalation","Through study completion, an average of 8 Weeks",{"measure":14,"description":15,"timeFrame":12},"Number of participants with Serious Adverse Events","A Serious Adverse Event (SAE) is any untoward medical occurrence that, at any dose:\n\n* Results in death, is life-threatening, or requires (or prolongs) hospitalization;\n* Results in persistent or significant disability\u002Fincapacity;\n* Is a congenital anomaly or birth defect; or\n* Is considered medically significant, requiring intervention to prevent one of the outcomes above.\n* Investigator judgment applies to other clinically important events that may not be immediately life-threatening but could jeopardize participant safety.\n\nAssessment of the safety and tolerability of GRT7041 after oral single and multiple-dose escalation",[17,21,24,27,30,33,36,39,42,45,48,51,55,58,61,64,67,71,73,75,79,81,84,86,88,90,92,94,96,98,101,103,105,109,111,113,116],{"measure":18,"description":19,"timeFrame":20},"Area Under the Concentration-Time Curve from 0 to 24 hours [(AUC)0-24] [SAD]","The total amount of the study drug (and metabolite) in the blood during the first 24 hours after it is taken.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.","Day 1 to Day 4 (Pre-dose, 0 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours, 18 hours, 24 hours, 30 hours, 36 hours, 48 hours, 72 hours) and Day 10 (240 hours)",{"measure":22,"description":23,"timeFrame":20},"Area Under the Plasma Concentration-Time Curve from Time 0 to the last measurable concentration (t) [AUC0-t] [SAD]","The total amount of the study drug (and metabolite) in the blood from the time it is taken until the last time a measurable level of the drug is found.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":25,"description":26,"timeFrame":20},"Area Under the Plasma Concentration-Time Curve from Time 0 extrapolated to infinity (AUC0-inf ) [SAD]","The total amount of the study drug (and metabolite) in the blood from the time it is taken until it has completely left the body.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":28,"description":29,"timeFrame":20},"Maximum Observed Plasma Concentration (Cmax) [SAD]","The maximum amount of the study drug (and metabolite) measured in the blood after taking the dose.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":31,"description":32,"timeFrame":20},"Time to Reach Maximum Observed Plasma Concentration (Tmax) [SAD]","The time it takes to reach the highest concentration of the study drug (and metabolite) in the blood after dosing.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":34,"description":35,"timeFrame":20},"Terminal Elimination Half-Life (t₁\u002F₂) [SAD]","The time it takes for the amount of study drug (and metabolite) in the blood to reduce by half after reaching its peak level.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":37,"description":38,"timeFrame":20},"Terminal Elimination Rate Constant (λz) [SAD]","The rate at which the study drug (and metabolite) is eliminated from the blood during the final phase after dosing.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":40,"description":41,"timeFrame":20},"Apparent Total Clearance of Drug From Plasma After Extravascular Administration (CL\u002FF) [SAD]","The amount of blood completely cleared of thestudy drug (and metabolite) per unit of time, taking into account how much of the drug is absorbed into the body.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":43,"description":44,"timeFrame":20},"Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz\u002FF) [SAD]","An estimate of how widely the study drug spreads through the body's tissues after it is absorbed.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":46,"description":47,"timeFrame":20},"Lag Time Before First Measurable Concentration (tlag) [SAD]","The time between when the study drug (and metabolite) is taken and when it first becomes measurable in the blood.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":49,"description":50,"timeFrame":20},"Time of Last Measurable Concentration (tlast) [SAD]","The last time point when a measurable amount of the study drug (and metabolite) is found in the blood.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":52,"description":53,"timeFrame":54},"Amount of Study Drug Excreted in Urine (Ae) [SAD]","The total amount of the study drug (and metabolite) that is passed out of the body through urine during a specific collection period.\n\nCollected only for one cohort in Part 1: SAD.\n\nAssessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.","Day 1 to Day 4 (from 0 hours to 72 hours)",{"measure":56,"description":57,"timeFrame":54},"Cumulative Amount of Study Drug Excreted in Urine (Cumulative Ae) [SAD]","The total amount of the study drug (and metabolite) eliminated in urine from the time of dosing up to the end of each collection period, showing how much of the drug has been removed from the body over time.\n\nCollected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":59,"description":60,"timeFrame":54},"Percentage of Dose Excreted in Urine (Ae%) [SAD].","The percentage of the total amount of the study drug (and metabolite) dose that is passed out in urine during each collection period.\n\nCollected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":62,"description":63,"timeFrame":54},"Cumulative Percentage of Dose Excreted in Urine (Cumulative Ae%) [SAD]","The total percentage of the study drug dose excreted in urine from dosing until the end of each collection period, showing how much of the drug has been eliminated over time.\n\nCollected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":65,"description":66,"timeFrame":54},"Renal Clearance of Study Drug (CLr) [SAD]","The rate at which the study drug (and metabolite) is removed from the blood by the kidneys and excreted in the urine.\n\nCollected only for one cohort in Part 1: SAD. Assessment of the PK of GRT7041 and its metabolite, GRT1093025, for single-dosing.",{"measure":68,"description":69,"timeFrame":70},"Area Under the Concentration-Time Curve from 0 to 24 hours [(AUC)0-24] [MAD]","Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing.","Day 1 (0 hours - 24 hours)",{"measure":72,"description":69,"timeFrame":70},"Maximum Observed Plasma Concentration (Cmax) [MAD]",{"measure":74,"description":69,"timeFrame":70},"Time to Reach Maximum Observed Plasma Concentration (Tmax) [MAD]",{"measure":76,"description":77,"timeFrame":78},"Area Under the Plasma Concentration-time Curve Over a Dose Interval at Steady State (AUCτ,ss) [MAD]","Assessment of the pharmacokinetics (PK) of GRT7041 and its metabolite, GRT1093025, for multiple-dosing","Day 14 - Day 17 (0 hours to 72 hours after last dose) and Day 21",{"measure":80,"description":77,"timeFrame":78},"Maximum Observed Plasma Concentration at Steady State (Cmax,ss) [MAD]",{"measure":82,"description":77,"timeFrame":83},"Minimum Observed Plasma Concentration at Steady State (Cmin,ss) [MAD]","Day 1, Day 2, Day 4, Day 6, Day 8, Day 10, and Day 12 to Day 17 and Day 21",{"measure":85,"description":77,"timeFrame":83},"Average Observed Plasma Concentration at Steady State (Cav.ss) [MAD]",{"measure":87,"description":77,"timeFrame":78},"Time to Reach Maximum Observed Plasma Concentration (Tmax) at Steady State (tmax,ss) [MAD]",{"measure":89,"description":77,"timeFrame":83},"Terminal Elimination Half-Life (t₁\u002F₂) [MAD]",{"measure":91,"description":77,"timeFrame":83},"Terminal Elimination Rate Constant (λz) [MAD]",{"measure":93,"description":77,"timeFrame":83},"Apparent Total Clearance of Drug From Plasma After Extravascular Administration (CL\u002FF) [MAD]",{"measure":95,"description":77,"timeFrame":83},"Apparent Volume of Distribution During the Terminal Phase After Extravascular Administration (Vz\u002FF) [MAD]",{"measure":97,"description":77,"timeFrame":78},"Time of Last Measurable Concentration (tlast) [MAD]",{"measure":99,"description":100,"timeFrame":20},"Maximum Observed Plasma Concentration (Cmax) [SAD] for fed and fasted state","Assessment of the effect of food on the PK of GRT7041 following single-dosing",{"measure":102,"description":100,"timeFrame":20},"Area Under the Plasma Concentration-Time Curve from Time 0 to the last measurable concentration (t) [AUC0-t] [SAD] for fed and fasted state",{"measure":104,"description":100,"timeFrame":20},"Area Under the Plasma Concentration-Time Curve from Time 0 extrapolated to infinity (AUC0-inf ) [SAD] for fed and fasted state",{"measure":106,"description":107,"timeFrame":108},"Area Under the Plasma Concentration-Time Curve from Time 0 to the last measurable concentration (t) [AUC0-t] of midazolam","PK parameters (AUC0-t, AUC0-inf, Cmax, tmax and t1\u002F2) of midazolam (index substrate) before and after treatment with GRT7041 over 14 days, and when administered alone and after single day and 14 days of treatment with GRT7041","Day -1, Day 1 and Day 14 (pre-dose, 0.25 hours, 0.5 hours, 1 hours, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 15 hours and 18 hours)",{"measure":110,"description":107,"timeFrame":108},"Area Under the Plasma Concentration-Time Curve from Time 0 extrapolated to infinity (AUC0-inf ) of midazolam",{"measure":112,"description":107,"timeFrame":108},"Maximum Observed Plasma Concentration (Cmax) of midazolam",{"measure":114,"description":115,"timeFrame":108},"Time to Reach Maximum Observed Plasma Concentration (Tmax) of midazolam","PK parameters (AUC0-t, AUC0-inf, Cmax, tmax and t1\u002F2) of midazolam (index substrate) before and after treatment with GRT7041 over 14 days",{"measure":117,"description":115,"timeFrame":108},"Terminal Elimination Half-Life (t₁\u002F₂) of midazolam",null,{"allocation":120,"interventionModel":121,"interventionModelDescription":118,"primaryPurpose":122,"observationalModel":118,"timePerspective":118,"maskingInfo":123},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":124,"maskingDescription":118,"whoMasked":125},"QUADRUPLE",[126,127,128,129],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR","The trial will consist of two parts:\n\n* Part 1: SAD with up to five cohorts SAD1 to SAD5 (n = 40). To be conducted in adult males and women of non-childbearing potential (WONCBP).\n* Part 2: MAD with up to three cohorts, MAD1 to MAD3 (n = 30) dosed once daily (QD) for a period of 14 days. To be conducted in adult males only.\n\nThe trial design also evaluate the potential interaction of GRT7041 with a CYP3A4 index substrate that will be assessed separately in all cohorts in Part 2 (MAD) of the trial.\n\nDosing in Parts 1 and 2 will be conducted under fasted conditions, except for the SAD3 cohort in Part 1 (SAD), where participants will also receive a standardized breakfast (SAD3b treatment) to assess the effect of food.",[132,139],{"label":133,"type":134,"description":135,"interventionNames":136},"Part 1: SAD","EXPERIMENTAL","With up to five cohorts SAD1 to SAD5 (n = 40). To be conducted in adult males and WONCBP",[137,138],"Drug: GRT7041 SAD","Drug: Placebo",{"label":140,"type":134,"description":141,"interventionNames":142},"Part 2: MAD","With up to three cohorts, MAD1 to MAD3 (n = 30) dosed once daily (QD) for a period of 14 days. To be conducted in adult males only.",[138,143,144],"Drug: Midazolam","Drug: GRT7041 MAD",[146,151,155,159],{"type":147,"name":148,"description":149,"armGroupLabels":150,"otherNames":118},"DRUG","GRT7041 SAD","Single ascending doses",[133],{"type":147,"name":152,"description":153,"armGroupLabels":154,"otherNames":118},"Placebo","Placebo to match GRT7041 dose strength",[133,140],{"type":147,"name":156,"description":157,"armGroupLabels":158,"otherNames":118},"Midazolam","Solution",[140],{"type":147,"name":160,"description":161,"armGroupLabels":162,"otherNames":118},"GRT7041 MAD","Multiple ascending doses",[140],[164,170],{"name":165,"role":166,"phone":167,"phoneExt":168,"email":169},"Grünenthal Clinical Trial Helpdesk","CONTACT","+49 241 569","3223","clinical-trials@grunenthal.com",{"name":171,"role":166,"phone":118,"phoneExt":118,"email":169},"Director Clinical Trials",[173],{"facility":174,"status":175,"city":176,"state":118,"zip":177,"country":178,"countryCode":179,"cosmosGeoPoint":180,"geoPoint":185,"contacts":186},"New Zealand Clinical Research (NZCR)","RECRUITING","Christchurch","8011","New Zealand","NZ",{"type":181,"coordinates":182},"Point",[183,184],172.63333,-43.53333,{"lat":184,"lon":183},[187,190],{"name":188,"role":166,"phone":118,"phoneExt":118,"email":189},"Cory Sellwood, MD","Cory.sellwood@nzcr.co.nz",{"name":188,"role":191,"phone":118,"phoneExt":118,"email":118},"PRINCIPAL_INVESTIGATOR",{"type":193,"investigatorFullName":118,"investigatorTitle":118,"investigatorAffiliation":118,"oldNameTitle":118,"oldOrganization":118},"SPONSOR","100615220","phase-1-a-first-in-human-trial-of-grt7041-in-healthy-participants-100615220",false,"NCT07289776","A First-in-human Trial of GRT7041 in Healthy Participants","A Randomized, Single-center, Double-blind, Placebo-controlled, First-in-human Trial With Single and Multiple Ascending Doses to Determine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GRT7041 in Healthy Participants.","Main Inclusion Criteria:\n\n1. The participant must be able to give signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n2. Participants must sign the ICF before any trial-related assessments.\n3. The participant is in good health as judged by the Investigator including medical history, physical examination, 12-lead ECG, vital signs (pulse rate, respiratory rate, systolic and diastolic BP), body temperature, and clinical laboratory parameters (clinical chemistry, hematology, coagulation and urinalysis) without clinically relevant deviations from reference ranges, unless further specified in the exclusion criteria.\n\nMain Exclusion Criteria:\n\n1. History of any of the following: cardiac impairment, renal impairment, pancreatitis, coagulation abnormalities.\n2. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk for treatment complications\u002F participation in the trial unsafe.\n3. Any disease or conditions known to interfere with the absorption, distribution, metabolism, or excretion of the IMP.\n4. Evidence or medical history of clinically significant and relevant psychiatric issues as assessed by the Investigator.\n5. Confirmed or suspected history of clinically relevant drug allergy.\n6. Major surgical procedure, within 30 days prior to ICF signing, or anticipation of need for a major surgical procedure during the trial.\n7. Blood loss of 500 mL or more (eg, owing to blood donation) within 90 days before Screening Visit.\n8. The participant has used any medication, including herbal remedies or over-the-counter medication within 2 weeks (or 5 half-lives, whichever is longer) before the start of the trial intervention or anticipated use during the trial, unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the trial.\n9. The participant is enrolled in another clinical trial unless it is an observational (non-interventional) clinical trial or during the follow-up period of an interventional trial) or has received an IMP in another clinical trial within 30 days before Day 1 or within 5 times the elimination half-life of the IMP, whichever is longer.\n10. Reluctance to comply with contraception requirements.\n11. Evidence or history of alcohol or drug abuse including positive or missing alcohol breath test or drugs of abuse test(s).",true,"ALL","18 Years","60 Years",{"count":206,"type":207},70,"ESTIMATED","INTERVENTIONAL",[210],"PHASE1","The purpose of this trial is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GRT7041 in healthy male and female (Women of non-childbearing potential) participants.\n\nThe trial duration will be up to approximately 6 weeks for participants in Part 1 (Single ascending dose \\[SAD\\]), except for participants taking part in the food effect cohort SAD3 where the trial duration will be up to approximately 8 weeks. The trial duration will be up to approximately 7 weeks in Part 2 (Multiple ascending dose \\[MAD\\]), and the Treatment Period will be up to 14 days (for Part 2).\n\nThe trial will include a Screening Visit, an in-house stay period and Follow-up (FU) Visit\u002FEnd-of-Trial (EoT) Visit.",[213],"Treatment of Pain","2026-02-18",{"date":216,"type":217},"2026-02-20","ACTUAL",{"date":219,"type":217},"2026-01-14",{"date":221,"type":207},"2026-08-28",{"name":5,"class":6},1]